Paul D Nathan

Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.

Michael Jeffers, Heikki Joensuu, Tim Eisen, 2012, The Lancet. Oncology.

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies

Vicky Goh, V. Goh, P. Nathan, 2010, Cancer biology & therapy.